Table 3A Prognostic value of CD3, CD8, CD4, CD57, CD68, CXCL9/MIG, PPARγ, and CXCL13/BCA1 in tumour tissue from patients without preop-RT after adjustment for anatomoclinical factors (tumour location, stage, grade, and adjuvant chemotherapy)
From: Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer
Relapse-free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|
n | HR | 95% CI | P | HR | 95% CI | P | |
CD3 | |||||||
CD3 ⩽80 cells per spot | 76 | 2.1 | 1.1–4.0 | 2.0 | 1.1–3.8 | ||
CD3 >80 cells per spot | 73 | 1 | 0.02 | 1 | 0.025 | ||
Missing | 9 | ||||||
CD4 | |||||||
CD4 ⩽2 cells per spot | 88 | 0.9 | 0.5–1.6 | 1.3 | 0.7–2.4 | ||
CD4 >2 cells per spot | 66 | 1 | 0.72 | 1 | 0.41 | ||
Missing | 4 | ||||||
CD8 | |||||||
CD8 ⩽8 cells per spot | 80 | 1.4 | 0.8–2.6 | 1.5 | 0.8–2.7 | ||
CD8 >8 cells per spot | 74 | 1 | 0.25 | 1 | 0.22 | ||
Missing | 4 | ||||||
CD57 | |||||||
CD57 ⩽2 cells per spot | 100 | 3.2 | 1.5–6.6 | 2.9 | 1.4–5.9 | ||
CD57 >2 cells per spot | 56 | 1 | 0.002 | 1 | 0.003 | ||
Missing | 2 | ||||||
CD68 | |||||||
CD68=0 cells per spot | 8 | 5.4 | 2.1–13.4 | 7.6 | 3.0–18.8 | ||
1⩽ CD68 ⩽10 cells per spot | 55 | 1.4 | 0.8–2.7 | 1.9 | 1.0–3.5 | ||
CD68 >10 cells per spot | 94 | 1 | 0.0016 | 1 | <0.0001 | ||
Missing | 1 | ||||||
CXCL9/MIG | |||||||
No staining | 36 | 3.3 | 1.3–8.4 | 3.2 | 1.2–8.4 | ||
Weak staining | 80 | 2.3 | 1.0–5.3 | 2.6 | 1.0–6.3 | ||
Moderate to strong | 42 | 1 | 0.041 | 1 | 0.063 | ||
Missing | 0 | ||||||
PPAR γ | |||||||
No staining | 73 | 1.3 | 0.7–2.5 | 0.7 | 0.4–1.4 | ||
Mild-to-moderate | 33 | 0.7 | 0.3–1.8 | 0.7 | 0.3–1.7 | ||
Strong staining | 51 | 1 | 0.38 | 1 | 0.57 | ||
Missing | 1 | ||||||
CXCL13/BCA1 | |||||||
No staining | 85 | 1.0 | 0.3–3.3 | 3.0 | 0.4–22.2 | ||
Few lymphocytes stained | 57 | 1.0 | 0.3–3.3 | 3.3 | 0.4–24.5 | ||
Numerous lymphocytes stained | 12 | 1 | 0.98 | 1 | 0.51 | ||
Missing | 4 | ||||||
